CCT5

Across TCGA pan-cancer cohorts, CCT5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCT5 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCT5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CCT5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

LUAD, LSCC, and GBM are the cancer types where CCT5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.609	0.927	.003	22	view →
LSCC	DFS	Quartile	II,III,IV	0.788	0.403	.024	8	view →
GBM	OS	Median	All	0.363	0.656	.009	8	view →
COAD	DFS	Median	III,IV	1.000	0.846	.049	6	view →
HNSC	OS	Median	III,IV	1.000	0.948	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CCT5–LUAD (OS)

Open the LUAD breakdown →